Results 251 to 260 of about 96,743 (331)

Nanoparticle‐encapsulated neuropeptide Y provides robust seizure protection in SCN1A‐derived epilepsy

Epilepsia, EarlyView.
Abstract Objective Neuropeptides have garnered great interest as potential treatments for epilepsy due to their impact on neuronal excitability through modulation of ion channels and neurotransmitter receptor activity. Neuropeptide Y (NPY) is a 36‐amino acid neuropeptide that is expressed primarily by γ‐aminobutyric acidergic (GABAergic) interneurons ...
Samantha L. Reed, Lauren M. Aiani, Eesha Faiz, Emmanuel Adediran, Morris Benveniste, Kevin S. Murnane, Martin D'Souza, Andrew Escayg, Jennifer C. Wong   +8 more
wiley   +1 more source

Novel low-cost atomizer design for intranasal drug delivery. [PDF]

J Anaesthesiol Clin Pharmacol
Sinha R, Kumar A, Ayub A.
europepmc   +1 more source

Bilateral laryngeal paralysis (aplegia) occurring late during the recovery of a horse after orthopaedic surgery

Equine Veterinary Education, EarlyView.
Summary A 9‐year‐old male castrated Standardbred was presented for evaluation of a comminuted right front first phalanx fracture. On initial clinical examination, mild haemoconcentration and increased vital parameters were noted. After overnight hospitalisation, the horse underwent general anaesthesia for surgical fracture repair.
I. Lutvikadic, K. Hopster, B. Driessen
wiley   +1 more source

The Intranasal Administration of Semaphorin 3A Inhibitor in a Mouse Model of Olfactory Disorder. [PDF]

Cureus
Murai A, Noda M, Shimizu A, Takahara J, Makihara S, Ando M.   +5 more
europepmc   +1 more source

Solving post‐anaesthetic respiratory obstruction: Being prepared is key

Equine Veterinary Education, EarlyView.
Summary Post‐anaesthetic respiratory obstruction in the horse is a relatively infrequent but immediately consequential occurrence. Prompt determination of the extent and source of the obstruction guides the next steps. Potential sources of the obstruction include the nares, occlusion of the nasal passages, and laryngotracheal dysfunction.
J. A. E. Hubbell
wiley   +1 more source

Carbon dot-lipidoid nanocarriers for superiorly biocompatible nasal mRNA cancer vaccination. [PDF]

J Nanobiotechnology
Kim H, Jeong H, Kim YA, Kim KS, Yun JW, Li F, Ling D, Na K.   +7 more
europepmc   +1 more source

Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess the efficacy of cannabis for the treatment of acute migraine. Background Preclinical and retrospective studies suggest cannabinoids may be effective in migraine treatment. However, there have been no randomized clinical trials examining the efficacy of cannabinoids for acute migraine.
Nathaniel M. Schuster, Mark S. Wallace, Thomas D. Marcotte, Dawn C. Buse, Euyhyun Lee, Lin Liu, Michelle Sexton   +6 more
wiley   +1 more source

A tissue-penetrably engineered deoxyribonuclease 1 to prevent nasal polyp formation in chronic rhinosinusitis. [PDF]

BMC Pharmacol Toxicol
Kwak SB, Khalmuratova R, Kim SJ, Shin HW, Park JW.   +4 more
europepmc   +1 more source

Assessment of the Effectiveness of Allergic Rhinitis Medications Using a Target Trial Emulation Approach Based on Mobile Health Data

Clinical &Experimental Allergy, EarlyView.
Nuno Lourenço‐Silva, Bernardo Sousa‐Pinto, Antonio Bognanni, Matteo Martini, Michal Ordak, Giovanni Paoletti, Sara Gil‐Mata, Rita Amaral, Anna Bedbrook, Patrizia Bonadonna, Luisa Brussino, G. Walter Canonica, João Coutinho‐Almeida, Alvaro A. Cruz, Wienczyslawa Czarlewski, Mark Dykewicz, Mattia Giovannini, Bilun Gemicioglu, Juan Carlos Ivancevich, Ludger Klimek, Violeta Kvedariene, Desiree E. Larenas‐Linnemann, Manuel Marques‐Cruz, André Moreira, Marek Niedoszytko, Ana Margarida Pereira, Nikolaos G. Papadopoulos, Nhân Pham‐Thi, Frederico S. Regateiro, Sanna K. Toppila‐Salmi, Boleslaw Samolinski, Joaquin Sastre, Luís Taborda‐Barata, Tuuli Thomander, Ilgım Vardaloğlu Koyuncu, Arunas Valiulis, Leticia de las Vecillas, Maria Teresa Ventura, Jolanta Walusiak‐Skorupa, Yi‐Kui Xiang, Oliver Pfaar, João A. Fonseca, Torsten Zuberbier, Holger J. Schünemann, Danilo di Bona, Jean Bousquet, Rafael José Vieira   +46 more
wiley   +1 more source

A phase 1 study of the breast milk and plasma pharmacokinetics of zavegepant 10 mg intranasal dose in healthy lactating women

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study evaluated the pharmacokinetics of zavegepant in human breast milk and plasma following a single, 10 mg dose of zavegepant nasal spray. Background Zavegepant nasal spray is a member of the gepant class of medications; small molecule inhibitors of the calcitonin gene‐related peptide receptor.
Abhijeet Jakate, Yan Weng, Ani Shkrodova, Ogert Fisniku, Ding Ding, Kayce Morton, Benjamin Maligalig, Pamela Garnick, Jing Liu, Mohamed H. Shahin   +9 more
wiley   +1 more source